Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2(-/tm1Som)), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.
Division of Nephrology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. torres.vicente@mayo.edu
Vicente E
VE
Torres
Xiaofang
X
Wang
Qi
Q
Qian
Stefan
S
Somlo
Peter C
PC
Harris
Vincent H
VH
Gattone
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000627:therapeutic use*; D000242:Cyclic AMP / Q000378:metabolism; D004195:Disease Models, Animal; D051379:Mice; D010641:Phenotype; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy*
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; C076251:mozavaptan; D000242:Cyclic AMP